Cure My Disease

Don't miss your cure!

 Log in / Sign up

CAR-T patients who get another cancer: did the gene therapy play a role?

NCT ID NCT06357754

Recruiting now Knowledge-focused Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at tumor samples from 50 people who developed a second cancer after receiving a Bristol-Myers Squibb CAR-T cell therapy for blood cancers like lymphoma or myeloma. Researchers will test the new tumors for traces of the gene-modified cells used in the original treatment. The goal is to see if those cells are present, which could help explain why some patients develop a second cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Idecabtagene vicleucel and Lisocabtagene maraleucel (gene-modified cell therapies)
What this could lead to
If successful, this could help understand whether the gene-modified cells from CAR-T therapy are involved in causing second cancers.
What could go wrong
This is a small, observational testing service, not a treatment trial. It may not find clear answers, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKAEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia Leukemia, B-Cell non-Hodgkin lymphoma plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKAEMIA MULTIPLE MYELOMA NON-HODGKIN LYMPHOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Huntsman Cancer Institute at the University of Utah

    RECRUITING

    Salt Lake City, Utah, 84112, United States

    Contact

  • Kantonsspital Aarau

    RECRUITING

    Aarau, 5001, Switzerland

    Contact Phone: •••-•••-••••

  • Local Institution - 0003

    WITHDRAWN

    Kumamoto, Kumamoto, 8608556, Japan

  • Local Institution - 0004

    WITHDRAWN

    Madison, Wisconsin, 53792, United States

  • Local Institution - 0016

    NOT_YET_RECRUITING

    Portland, Oregon, 97239-3098, United States

    Contact

  • Toyokawa City Hospital

    RECRUITING

    Toyokawa, Aichi-ken, 442-8561, Japan

    Contact

  • Universitaetsklinikum Essen (AoR)

    RECRUITING

    Essen, 45147, Germany

    Contact Phone: •••-•••-••••

  • Ut Southwestern

    RECRUITING

    Dallas, Texas, 75235, United States

    Contact Phone: •••-•••-••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.